Skip to content

Study · Animal study (in vivo) · rat · 1996

10 results

Salutary and prophylactic effect of pentadecapeptide BPC 157 on acute pancreatitis and concomitant gastroduodenal lesions in rats.

Sikirić P, Seiwerth S, Grabarević Z, Rucman R, Petek M, Jagić V, Turković B, Rotkvić I, Mise S, Zoricić I, Jurina L, Konjevoda P and 8 more

Show all authors

Hanzevacki M, Ljubanović D, Separović J, Gjurasin M, Bratulić M, Artuković B, Jelovac N, Buljat G

Digestive diseases and sciences1 Jul 1996Cited by 25 (Europe PMC)

PMID8689934 (opens in a new tab)DOI10.1007/bf02088582 (opens in a new tab)PepBankPUB-08689934
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with bile duct ligation-induced acute pancreatitis, BPC‑157 given before ligation gave strong pancreas protection.

    In plain wordsIn rats with pancreatitis, BPC‑157 given before the injury strongly protected the pancreas.

    Peptide
    BPC-157
    Outcome
    DecreasePancreas protection, prophylactic regimen
    Study

    ratn: not reported in source

    Bile duct ligation-induced acute pancreatitis
    Comparator
    Control
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    10 microg, 10 ng/kg body wt · intraperitoneal or intragastricAs given in this study (rat).

    Source sentences

    Summary
    In the pretreatment regimen, a strong pancreas protection was obtained.
    2 context sentences
    Summary · context
    In the present study, BPC 157 was tested as either a protective or healing agent in bile duct ligation-induced acute pancreatitis in rats.
    Summary · context
    BPC 157 (10 microg, 10 ng/kg body wt, intraperitoneally or intragastrically) was given prophylactically 1 hr before ligation, whereas the therapy was given once daily beginning with the 24 hr following ligation (last application 24 hr before killing).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with already established severe acute pancreatitis, BPC‑157 therapy had an obvious salutary effect.

    In plain wordsIn rats with established pancreatitis, BPC‑157 given as treatment had a clear beneficial effect.

    Peptide
    BPC-157
    Outcome
    DecreasePancreatitis, therapy regimen
    Study

    ratn: not reported in source

    Bile duct ligation-induced acute pancreatitis
    Comparator
    Control
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    10 microg, 10 ng/kg body wt · intraperitoneal or intragastricAs given in this study (rat).

    Source sentences

    Summary
    When applied in the condition of already established severe acute pancreatitis, an obvious salutory effect was consistently noted.
    2 context sentences
    Summary · context
    In the present study, BPC 157 was tested as either a protective or healing agent in bile duct ligation-induced acute pancreatitis in rats.
    Summary · context
    BPC 157 (10 microg, 10 ng/kg body wt, intraperitoneally or intragastrically) was given prophylactically 1 hr before ligation, whereas the therapy was given once daily beginning with the 24 hr following ligation (last application 24 hr before killing).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with acute pancreatitis, BPC-treated rats had consistently less pancreatic necrosis.

    In plain wordsIn rats with pancreatitis, BPC‑157 treatment led to less pancreatic tissue death.

    Peptide
    BPC-157
    Outcome
    DecreasePancreatic necrosis
    Study

    ratn: not reported in source

    Bile duct ligation-induced acute pancreatitis
    Comparator
    Control
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    10 microg, 10 ng/kg body wt · intraperitoneal or intragastricAs given in this study (rat).

    Source sentences

    Summary
    Assessing the appearance of the necrosis, edema, neutrophils, and mononuclears, consistently less necrosis, edema, and neutrophils, but more mononuclears, were found in BPC-treated rats.
    2 context sentences
    Summary · context
    In the present study, BPC 157 was tested as either a protective or healing agent in bile duct ligation-induced acute pancreatitis in rats.
    Summary · context
    BPC 157 (10 microg, 10 ng/kg body wt, intraperitoneally or intragastrically) was given prophylactically 1 hr before ligation, whereas the therapy was given once daily beginning with the 24 hr following ligation (last application 24 hr before killing).
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats with acute pancreatitis, BPC-treated rats had consistently less pancreatic edema.

    In plain wordsIn rats with pancreatitis, BPC‑157 treatment led to less pancreatic swelling.

    Peptide
    BPC-157
    Outcome
    DecreasePancreatic edema
    Study

    ratn: not reported in source

    Bile duct ligation-induced acute pancreatitis
    Comparator
    Control
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    10 microg, 10 ng/kg body wt · intraperitoneal or intragastricAs given in this study (rat).

    Source sentences

    Summary
    Assessing the appearance of the necrosis, edema, neutrophils, and mononuclears, consistently less necrosis, edema, and neutrophils, but more mononuclears, were found in BPC-treated rats.
    2 context sentences
    Summary · context
    In the present study, BPC 157 was tested as either a protective or healing agent in bile duct ligation-induced acute pancreatitis in rats.
    Summary · context
    BPC 157 (10 microg, 10 ng/kg body wt, intraperitoneally or intragastrically) was given prophylactically 1 hr before ligation, whereas the therapy was given once daily beginning with the 24 hr following ligation (last application 24 hr before killing).
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats with acute pancreatitis, BPC-treated rats had consistently fewer neutrophils in the pancreas.

    In plain wordsIn rats with pancreatitis, BPC‑157 treatment led to fewer neutrophils in the pancreas.

    Peptide
    BPC-157
    Outcome
    DecreasePancreatic neutrophil infiltration
    Study

    ratn: not reported in source

    Bile duct ligation-induced acute pancreatitis
    Comparator
    Control
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    10 microg, 10 ng/kg body wt · intraperitoneal or intragastricAs given in this study (rat).

    Source sentences

    Summary
    Assessing the appearance of the necrosis, edema, neutrophils, and mononuclears, consistently less necrosis, edema, and neutrophils, but more mononuclears, were found in BPC-treated rats.
    2 context sentences
    Summary · context
    In the present study, BPC 157 was tested as either a protective or healing agent in bile duct ligation-induced acute pancreatitis in rats.
    Summary · context
    BPC 157 (10 microg, 10 ng/kg body wt, intraperitoneally or intragastrically) was given prophylactically 1 hr before ligation, whereas the therapy was given once daily beginning with the 24 hr following ligation (last application 24 hr before killing).
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In rats with acute pancreatitis, BPC-treated rats had more mononuclear cells in the pancreas.

    In plain wordsIn rats with pancreatitis, BPC‑157 treatment led to more mononuclear immune cells in the pancreas.

    Peptide
    BPC-157
    Outcome
    IncreasePancreatic mononuclear cells
    Study

    ratn: not reported in source

    Bile duct ligation-induced acute pancreatitis
    Comparator
    Control
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    10 microg, 10 ng/kg body wt · intraperitoneal or intragastricAs given in this study (rat).

    Source sentences

    Summary
    Assessing the appearance of the necrosis, edema, neutrophils, and mononuclears, consistently less necrosis, edema, and neutrophils, but more mononuclears, were found in BPC-treated rats.
    2 context sentences
    Summary · context
    In the present study, BPC 157 was tested as either a protective or healing agent in bile duct ligation-induced acute pancreatitis in rats.
    Summary · context
    BPC 157 (10 microg, 10 ng/kg body wt, intraperitoneally or intragastrically) was given prophylactically 1 hr before ligation, whereas the therapy was given once daily beginning with the 24 hr following ligation (last application 24 hr before killing).
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In rats with acute pancreatitis, the BPC‑157 pretreatment regimen gave a markedly lower rise in serum amylase relative to control data.

    In plain wordsIn rats with pancreatitis, BPC‑157 given beforehand led to a much smaller rise in the blood enzyme amylase.

    Peptide
    BPC-157
    Outcome
    DecreaseSerum amylase rise, pretreatment regimen
    Study

    ratn: not reported in source

    Bile duct ligation-induced acute pancreatitis
    Comparator
    Control
    Outcome group
    Inflammation markers · Gastrointestinal
    Studied dose
    10 microg, 10 ng/kg body wt · intraperitoneal or intragastricAs given in this study (rat).

    Source sentences

    Summary
    in studies of the serum amylase values, relative to control data, a markedly lower rise (BPC pretreatment regimen)
    2 context sentences
    Summary · context
    In the present study, BPC 157 was tested as either a protective or healing agent in bile duct ligation-induced acute pancreatitis in rats.
    Summary · context
    BPC 157 (10 microg, 10 ng/kg body wt, intraperitoneally or intragastrically) was given prophylactically 1 hr before ligation, whereas the therapy was given once daily beginning with the 24 hr following ligation (last application 24 hr before killing).
  8. 08AnimalAnimal study (in vivo)Safety outcome

    In rats with acute pancreatitis, the BPC‑157 therapy regimen was associated with a worsening of the already raised serum amylase values.

    In plain wordsIn rats with pancreatitis, the blood enzyme amylase, already high, got worse with BPC‑157 given as treatment.

    Peptide
    BPC-157
    Outcome
    IncreaseSerum amylase, therapy regimen
    Study

    ratn: not reported in source

    Bile duct ligation-induced acute pancreatitis
    Comparator
    Control
    Outcome group
    Inflammation markers · Gastrointestinal
    Studied dose
    10 microg, 10 ng/kg body wt · intraperitoneal or intragastricAs given in this study (rat).

    Source sentences

    Summary
    as well as a worsening of the already raised values (BPC therapy regimen) was noted.
    2 context sentences
    Summary · context
    In the present study, BPC 157 was tested as either a protective or healing agent in bile duct ligation-induced acute pancreatitis in rats.
    Summary · context
    BPC 157 (10 microg, 10 ng/kg body wt, intraperitoneally or intragastrically) was given prophylactically 1 hr before ligation, whereas the therapy was given once daily beginning with the 24 hr following ligation (last application 24 hr before killing).
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In bile duct-ligated rats, BPC‑157 had a positive influence on the gastric lesion course in both the pre- and posttreatment regimen.

    In plain wordsIn rats with bile duct ligation, BPC‑157 improved stomach lesions, whether given before or after the injury.

    Peptide
    BPC-157
    Outcome
    DecreaseGastric lesions in bile duct-ligated rats
    Study

    ratn: not reported in source

    Bile duct ligation-induced acute pancreatitis
    Comparator
    Control
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    10 microg, 10 ng/kg body wt · intraperitoneal or intragastricAs given in this study (rat).

    Source sentences

    Summary
    a positive influence of BPC 157 on the gastric and duodenal lesion course in bile duct-ligated rats was noted in both the pre- and posttreatment regimen
    2 context sentences
    Summary · context
    In the present study, BPC 157 was tested as either a protective or healing agent in bile duct ligation-induced acute pancreatitis in rats.
    Summary · context
    BPC 157 (10 microg, 10 ng/kg body wt, intraperitoneally or intragastrically) was given prophylactically 1 hr before ligation, whereas the therapy was given once daily beginning with the 24 hr following ligation (last application 24 hr before killing).
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In bile duct-ligated rats, BPC‑157 had a positive influence on the duodenal lesion course in both the pre- and posttreatment regimen.

    In plain wordsIn rats with bile duct ligation, BPC‑157 improved duodenal lesions, whether given before or after the injury.

    Peptide
    BPC-157
    Outcome
    DecreaseDuodenal lesions in bile duct-ligated rats
    Study

    ratn: not reported in source

    Bile duct ligation-induced acute pancreatitis
    Comparator
    Control
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    10 microg, 10 ng/kg body wt · intraperitoneal or intragastricAs given in this study (rat).

    Source sentences

    Summary
    a positive influence of BPC 157 on the gastric and duodenal lesion course in bile duct-ligated rats was noted in both the pre- and posttreatment regimen
    2 context sentences
    Summary · context
    In the present study, BPC 157 was tested as either a protective or healing agent in bile duct ligation-induced acute pancreatitis in rats.
    Summary · context
    BPC 157 (10 microg, 10 ng/kg body wt, intraperitoneally or intragastrically) was given prophylactically 1 hr before ligation, whereas the therapy was given once daily beginning with the 24 hr following ligation (last application 24 hr before killing).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.